CD274 and non-small cell lung carcinoma: In patients with metastatic NSCLC and no prior systemic therapy, pembrolizumab was recently approved in the United States for the treatment of patients with PD-L1 expression ≥50% based on the results of the KEYNOTE-024 (NCT02142738) study [7].